Live feed08:45:00·15mPRReleasevia QuantisnowOS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic OsteosarcomaByQuantisnow·Wall Street's wire, on your screen.OSTX· OS Therapies IncorporatedHealth Care
